BGIM
OACC

Boussard & Gavaudan Investment Management’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.62M Hold
720,000
– – 0.72% 27
2025
Q4 		$7.65M Sell
720,000
-30,000
-4% -$317K 0.58% 46
2025
Q3 		$7.89M Hold
750,000
– – 0.98% 28
2025
Q2 		$7.87M Hold
750,000
– – 1.01% 28
2025
Q1 		$7.67M Hold
750,000
– – 1.2% 24
2024
Q4 		$7.6M Buy
+750,000
New +$7.48M 0.63% 41

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.44% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Boussard & Gavaudan Investment Management's OACC Position: Q1 2026 in Review

Boussard & Gavaudan Investment Management held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q1 2026 at 720,000 shares worth $7.62M. The position accounts for 0.72% of the portfolio, ranked #27.

Boussard & Gavaudan Investment Management first reported a position in OACC in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.89M in Q3 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Boussard & Gavaudan Investment Management held 720,000 shares of Oaktree Acquisition Corp III Life Sciences worth $7.62M as of Q1 2026.
  • Boussard & Gavaudan Investment Management left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences made up 0.72% of Boussard & Gavaudan Investment Management's portfolio in Q1 2026, its #27 holding.
  • Boussard & Gavaudan Investment Management first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and has held it in 6 quarters since.
  • Boussard & Gavaudan Investment Management's Oaktree Acquisition Corp III Life Sciences position peaked at $7.89M in Q3 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.